Elevated SLC1A5 associated with poor prognosis and therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Elevated SLC1A5 associated with poor prognosis and therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma ; volume:22 ; number:1 ; day:6 ; month:6 ; year:2024 ; pages:1-15 ; date:12.2024
Journal of translational medicine ; 22, Heft 1 (6.6.2024), 1-15, 12.2024
- Creator
-
Zhang, Guixiong
Xiao, Yitai
Tan, Jizhou
Liu, Hang
Fan, Wenzhe
Li, Jiaping
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12967-024-05298-1
- URN
-
urn:nbn:de:101:1-2408132136333.630321007721
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:46 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Zhang, Guixiong
- Xiao, Yitai
- Tan, Jizhou
- Liu, Hang
- Fan, Wenzhe
- Li, Jiaping
- SpringerLink (Online service)
Other Objects (12)
Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma
Transarterial chemoembolization with drug-eluting beads versus conventional transarterial chemoembolization in locally advanced hepatocellular carcinoma
Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma
Prognosis of transarterial chemoembolization-sorafenib compared to transarterial chemoembolization-alone in hepatocellular carcinoma stage C: a systematic review
PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma
Applicability of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma
Transarterial chemoembolization with molecular targeted therapies plus camrelizumab for recurrent hepatocellular carcinoma
Obstructive Jaundice Following Transarterial Chemoembolization for Hepatocellular Carcinoma with Bile Duct Invasion
Ischemic Duodenal Ulceration after Transarterial Chemoembolization for Hepatocellular Carcinoma: A Case Report
Dynamic CT angiography for therapy evaluation after transarterial chemoembolization of hepatocellular carcinoma
Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma
Transarterial Chemoembolization – Status Quo in Germany
Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma
Transarterial chemoembolization with drug-eluting beads versus conventional transarterial chemoembolization in locally advanced hepatocellular carcinoma
Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma
Prognosis of transarterial chemoembolization-sorafenib compared to transarterial chemoembolization-alone in hepatocellular carcinoma stage C: a systematic review
PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma
Applicability of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma
Transarterial chemoembolization with molecular targeted therapies plus camrelizumab for recurrent hepatocellular carcinoma
Obstructive Jaundice Following Transarterial Chemoembolization for Hepatocellular Carcinoma with Bile Duct Invasion
Ischemic Duodenal Ulceration after Transarterial Chemoembolization for Hepatocellular Carcinoma: A Case Report
Dynamic CT angiography for therapy evaluation after transarterial chemoembolization of hepatocellular carcinoma
Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma
Transarterial Chemoembolization – Status Quo in Germany
Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma
Transarterial chemoembolization with drug-eluting beads versus conventional transarterial chemoembolization in locally advanced hepatocellular carcinoma
Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma
Prognosis of transarterial chemoembolization-sorafenib compared to transarterial chemoembolization-alone in hepatocellular carcinoma stage C: a systematic review
PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma
Applicability of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma
Transarterial chemoembolization with molecular targeted therapies plus camrelizumab for recurrent hepatocellular carcinoma
Obstructive Jaundice Following Transarterial Chemoembolization for Hepatocellular Carcinoma with Bile Duct Invasion
Ischemic Duodenal Ulceration after Transarterial Chemoembolization for Hepatocellular Carcinoma: A Case Report
Dynamic CT angiography for therapy evaluation after transarterial chemoembolization of hepatocellular carcinoma
Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma